Text Size

Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.

This study has been withdrawn prior to enrollment.
(no patients recruited)
Sponsor:
Collaborator:
The Royal Norwegian Ministry of Health
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00184288
First received: September 13, 2005
Last updated: November 1, 2011
Last verified: October 2011
History of Changes
  Purpose

The aim of the study is to investigate the feasibility of in vivo single volume MR spectroscopy in evaluation of treatment response in patients with brain metastases, using 3T MR instrument. In order to optimize and avoid ineffective treatment of patients with brain metastases, in vivo MR spectroscopy can be an useful tool.


Condition
Neoplasm Metastasis
Lung Neoplasms
Breast Neoplasms
Melanoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Single Volume 1H MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Norwegian University of Science and Technology:

Enrollment: 0
Study Start Date: November 2004
Study Completion Date: December 2010
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with brain metastases

Criteria

Inclusion Criteria:

  • Clinical diagnosis of brain metastases

Exclusion Criteria:

  • children
  • pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00184288

Locations
Norway
Norwegian University of Science and Technology, Faculty of Medicine
Trondheim, Norway, N-7489
Sponsors and Collaborators
Norwegian University of Science and Technology
The Royal Norwegian Ministry of Health
Investigators
Study Director: Steinar Lundgren, MD PhD Cancer clinic, St.Olavs Hospital Trondheim University Hospital
  More Information

No publications provided

Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00184288     History of Changes
Other Study ID Numbers: 11184
Study First Received: September 13, 2005
Last Updated: November 1, 2011
Health Authority: Norway: Norwegian Social Science Data Services

Keywords provided by Norwegian University of Science and Technology:
Lipid
choline
metastasis
magnetic resonance spectroscopy
treatment response

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms
Lung Neoplasms
Melanoma
Neoplasm Metastasis
Neoplasms, Second Primary
Neoplasms by Site
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
 Lung Diseases
Respiratory Tract Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on May 19, 2013